Dexanabinol: Phase I ongoing

e-Therapeutics said dose-escalation will continue in an investigator-led, U.S. Phase I trial of IV ETS2101 administered on days 1, 8 and 15 of a 21-day cycle in up to 45 patients. The company said 15 ...